ACKNOWLEDGEMENT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

DATE OF RELEASE/EXPIRATION

This activity was released on December 8, 2023 and is valid until December 8, 2024. Requests for credit must be made no later than December 8, 2024

TARGET AUDIENCE

The primary target audience for this activity are medical oncologists, thoracic oncologists, pathologists, oncology nurse practitioners, oncology physician assistants.

STATEMENT OF NEED/PROGRAM OVERVIEW

Overall care for patients with advanced NSCLC can be optimized when clinicians are up to date with the latest immunotherapies, understand how PD-L1 levels affect response to immunotherapy, and are able to select the optimal treatment for each patient. Coordination among multidisciplinary team members and communication with patients for clinical decision-making are critical for improving patient outcomes. Join thoracic oncologists Dr. Julie Brahmer and Dr. Hossein Borghaei to review practice-changing data on the efficacy and safety of new and emerging treatment strategies with checkpoint inhibitors. The panel will also discuss recent therapy approvals, selection of patients based on PD-L1 and mutational status, minimizing immune-related adverse events, and improving patient quality of life.  

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Evaluate efficacy data from practice-changing clinical trials on immune checkpoint inhibitors for first-line treatment of NSCLC
• Outline adverse events associated with immunotherapies and approaches to mitigate these effects
• Discuss the effect of PD-L1 expression on outcomes in patients with NSCLC treated with immune checkpoint inhibitors
• Outline strategies to individualize treatment plans for patients with NSCLC through multidisciplinary care and shared decision-making

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a score of 75% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:  

Name of Faculty or Presenter	Conflicts of Interest
Julie Renee Brahmer, MD Co-director of the Upper Aerodigestive Department Bloomberg~Kimmel Institute for Cancer Immunotherapy Marilyn Meyerhoff Professor of Thoracic OncologyJohns Hopkins Kimmel Cancer Center	Consultant/Advisor/Speaker: Amgen, AstraZenaca, Bristol Myers Squibb, Eli Lilly, Genentech/Roche, GlaxoSmith/Kline, Merk, Sanofi
Hossein Borghaei, DO, MS Chief of Thoracic Medical OncologyProfessor, Department of Oncology/HematologyThe Gloria and Edmund M. Dunn Chair in Thoracic Malignancies Fox Chase Cancer Center	Consultant/Advisor/Speaker: BMS, Lilly, Genentech, Pfizer, Merck, EMD-Serono, Boehringer Ingelheim, Astra Zeneca, Novartis, Genmab, Regeneron, BioNTech, Amgen, Axiom, PharmaMar, Takeda, Mirati, Daiichi, Guardant, Natera, Oncocyte, Beigene, iTEO, Jazz, Janssen, Puma, BerGenBio, Bayer, Iobiotech Researcher: Amgen, BMS, Lilly

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For additional information about the accreditation of this activity, please visit https://partnersed.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.